Skip to main content
. 2021 Mar 31;11:7282. doi: 10.1038/s41598-021-85227-0

Figure 1.

Figure 1

The percentage of onset of viral clearance (SARS-CoV-2 PCR negative conversion) in the two COVID-19 study groups; Group 1 (hydroxychloroquine and oseltamivir) and Group 2 (favipiravir) within 2 weeks of treatment.